Interações medicamentosas em pacientes com síndrome metabólica prévia internados com diagnóstico para Covid-19: uma análise multifatorial

Abstract

In 2019, in the city of Wuhan, China, a new virus called SARS-CoV-2 was identified, triggering the COVID-19 pandemic and impacting global public health. This infection, particularly, resulted in severe complications in patients with pre-existing comorbidities, such as metabolic syndrome, a condition that significantly increased the number of hospitalizations. Additionally, due to the clinical complexity of these patients, the use of five or more medications is common, which elevates the risk of harmful drug interactions. Therefore, further research is needed to provide comprehensive and specialized care to these patients. With this purpose, the present study aimed to investigate the sociodemographic data and drug interactions in COVID-19 patients with metabolic syndrome admitted to a teaching hospital in the interior of Rio Grande do Sul. Inclusion criteria encompassed patients over 18 years of age, of both sexes, admitted between March 2020 and May 2022. The sample consisted of 39 medical records, predominantly of white married women, with a mean age close to 60 years and low educational level, subjected to polypharmacy, with a mean length of hospital stay of 14 days and hospital discharge in the majority of cases. A positive association was observed between the number of medications, drug interactions, and length of hospital stay. Furthermore, the increase in medication use during hospital discharge highlights the need to understand the complexity of treatment and the health condition of these patients. Therefore, it is essential to prioritize individualized care and clinical management for hospitalized patients with this infection and multiple comorbidities.